adjuvanted Arepanrix — Competitive Intelligence Brief

adjuvanted Arepanrix (adjuvanted Arepanrix) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adjuvanted inactivated influenza vaccine. Area: Immunology / Infectious Disease.

marketed Adjuvanted inactivated influenza vaccine H1N1 influenza virus hemagglutinin and neuraminidase antigens Immunology / Infectious Disease Biologic

Target snapshot

adjuvanted Arepanrix (adjuvanted Arepanrix) — University of British Columbia. Arepanrix is an adjuvanted pandemic influenza vaccine that stimulates immune response against H1N1 influenza virus through a combination of viral antigen and an immune-enhancing adjuvant.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
adjuvanted Arepanrix TARGET	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Adjuvanted pandemic influenza candidate vaccine	Adjuvanted pandemic influenza candidate vaccine	GlaxoSmithKline	phase 3	Adjuvanted inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adjuvanted inactivated influenza vaccine class)

1. GlaxoSmithKline · 1 drug in this class
2. University of British Columbia · 1 drug in this class